Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deudextromethorphan - Avanir Pharmaceuticals

Next Previous
Drug Profile

Deudextromethorphan - Avanir Pharmaceuticals

Alternative Names: AVP-786; CTP-786; d-DM; Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]; Deuterated dextromethorphan plus ultra low dose quinidine; Deuterated DM plus ultra low dose quinidine; Deuterated-dextromethorphan; Deuterated-DM

Latest Information Update: 14 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Concert Pharmaceuticals
  • Developer Avanir Pharmaceuticals
  • Class Antidepressants; Antipsychotics; Antitussives; Behavioural disorder therapies; Morphinans; Neuroprotectants; Opioid analgesics; Organic deuterium compounds; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; KATP channel inhibitors; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Agitation
  • Phase II/III Schizophrenia
  • Phase II Impulse control disorders; Major depressive disorder; Neurodegenerative disorders
  • No development reported Neuropathic pain; Psychiatric disorders

Most Recent Events

  • 12 Feb 2024 Efficacy and adverse event data from a phase III trial in Agitation released by Otsuka Pharmaceutical
  • 23 May 2023 Otsuka Pharmaceutical Development & Commercialization terminates phase-II/III trial in Schizophrenia (In adults) in Puerto Rico, Poland, Hungary, Bulgaria, Spain and USA (PO) based on the interim analysis outcome and recommendation by the data monitoring committee (DMC) (NCT03896945)
  • 06 Mar 2023 Concert Pharmaceuticals has been acquired by Sun Pharmaceutical Industries
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top